CN108463251A - 含有培美曲塞或其药学上可接受的盐的稳定药物组合物 - Google Patents

含有培美曲塞或其药学上可接受的盐的稳定药物组合物 Download PDF

Info

Publication number
CN108463251A
CN108463251A CN201680073091.9A CN201680073091A CN108463251A CN 108463251 A CN108463251 A CN 108463251A CN 201680073091 A CN201680073091 A CN 201680073091A CN 108463251 A CN108463251 A CN 108463251A
Authority
CN
China
Prior art keywords
pemetrexed
stability
monothioglycerol
composition
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680073091.9A
Other languages
English (en)
Chinese (zh)
Inventor
周珉载
徐惠珍
朴信政
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chong Kun Dang Corp
Original Assignee
Chong Kun Dang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Corp filed Critical Chong Kun Dang Corp
Publication of CN108463251A publication Critical patent/CN108463251A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201680073091.9A 2015-12-14 2016-12-13 含有培美曲塞或其药学上可接受的盐的稳定药物组合物 Pending CN108463251A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020150178339A KR101693675B1 (ko) 2015-12-14 2015-12-14 페메트렉시드 또는 그의 약제학적으로 허용가능한 염을 함유하는 안정화된 약학조성물
KR10-2015-0178339 2015-12-14
PCT/KR2016/014594 WO2017105059A1 (ko) 2015-12-14 2016-12-13 페메트렉시드 또는 그의 약제학적으로 허용가능한 염을 함유하는 안정화된 약학조성물

Publications (1)

Publication Number Publication Date
CN108463251A true CN108463251A (zh) 2018-08-28

Family

ID=57832487

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680073091.9A Pending CN108463251A (zh) 2015-12-14 2016-12-13 含有培美曲塞或其药学上可接受的盐的稳定药物组合物

Country Status (9)

Country Link
US (1) US10792285B2 (https=)
EP (1) EP3391908A4 (https=)
JP (3) JP2019502751A (https=)
KR (1) KR101693675B1 (https=)
CN (1) CN108463251A (https=)
HK (1) HK1255313A1 (https=)
MY (1) MY191043A (https=)
PH (1) PH12018501274A1 (https=)
WO (1) WO2017105059A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112138250A (zh) * 2019-06-28 2020-12-29 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
WO2023237093A1 (zh) * 2022-06-09 2023-12-14 上海云晟研新生物科技有限公司 培美曲塞二钠液体组合物、其制备方法及应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202000204A (zh) * 2018-06-20 2020-01-01 日商日本化藥股份有限公司 培美曲塞鈉注射用溶液製劑及其製造方法
JP2024006619A (ja) 2022-07-04 2024-01-17 セイコーエプソン株式会社 印刷装置、情報処理装置、情報処理システム、処理方法、及び、プログラム

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1396828A (zh) * 2000-02-04 2003-02-12 伊莱利利公司 含有培美西德以及一硫代甘油l－半胱氨酸或巯乙酸的药物组合物
JP2014237607A (ja) * 2013-06-07 2014-12-18 ニプロ株式会社 ペメトレキセドを含む注射用組成物
WO2015050230A1 (ja) * 2013-10-03 2015-04-09 富士フイルム株式会社 注射液製剤及びその製造方法
JP2015127300A (ja) * 2013-12-27 2015-07-09 富士フイルム株式会社 注射液製剤及びその製造方法
WO2015145911A1 (ja) * 2014-03-28 2015-10-01 富士フイルム株式会社 注射液製剤及びその製造方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0162654B1 (ko) 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
US6686365B2 (en) 2000-02-04 2004-02-03 Eli Lilly And Company Pharmaceutical composition
WO2012015810A2 (en) * 2010-07-28 2012-02-02 Eagle Pharmaceuticals, Inc. Pharmaceutical compositions containing pemetrexed having extended storage stability
KR20130122065A (ko) 2012-04-30 2013-11-07 씨제이제일제당 (주) 페메트렉시드를 함유하는 안정화된 주사용 액상 제제
EP2666463A1 (en) * 2012-05-21 2013-11-27 Synthon BV Stabilized liquid composition comprising pemetrexed
EP2854768B2 (en) * 2012-05-30 2025-06-18 Fresenius Kabi Oncology Limited Pharmaceutical compositions of pemetrexed
DE102012010774A1 (de) * 2012-05-31 2013-12-05 Stada Arzneimittel Ag Pharmazeutische Pemetrexed-Lösung
KR101260636B1 (ko) 2012-11-29 2013-05-13 씨제이제일제당 (주) 안정화된 페메트렉시드 제제
KR101485243B1 (ko) 2013-05-08 2015-01-21 씨제이헬스케어 주식회사 안정화된 페메트렉시드 제제
KR101574875B1 (ko) * 2014-02-13 2015-12-04 건양대학교산학협력단 안정화된 페니실린 복합 현탁 제제
WO2016151365A1 (en) * 2015-03-26 2016-09-29 Ftf Pharma Private Limited Pharmaceutical composition of pemetrexed
KR101919436B1 (ko) * 2015-05-28 2018-11-16 주식회사 삼양바이오팜 안정화된 약학 조성물 및 그의 제조방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1396828A (zh) * 2000-02-04 2003-02-12 伊莱利利公司 含有培美西德以及一硫代甘油l－半胱氨酸或巯乙酸的药物组合物
JP2014237607A (ja) * 2013-06-07 2014-12-18 ニプロ株式会社 ペメトレキセドを含む注射用組成物
WO2015050230A1 (ja) * 2013-10-03 2015-04-09 富士フイルム株式会社 注射液製剤及びその製造方法
JP2015127300A (ja) * 2013-12-27 2015-07-09 富士フイルム株式会社 注射液製剤及びその製造方法
WO2015145911A1 (ja) * 2014-03-28 2015-10-01 富士フイルム株式会社 注射液製剤及びその製造方法

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112138250A (zh) * 2019-06-28 2020-12-29 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
CN112138250B (zh) * 2019-06-28 2023-04-14 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
WO2023237093A1 (zh) * 2022-06-09 2023-12-14 上海云晟研新生物科技有限公司 培美曲塞二钠液体组合物、其制备方法及应用
CN117693334A (zh) * 2022-06-09 2024-03-12 上海云晟研新生物科技有限公司 培美曲塞二钠液体组合物、其制备方法及应用

Also Published As

Publication number Publication date
PH12018501274A1 (en) 2019-02-04
JP2020125359A (ja) 2020-08-20
HK1255313A1 (zh) 2019-08-16
MY191043A (en) 2022-05-30
EP3391908A1 (en) 2018-10-24
WO2017105059A1 (ko) 2017-06-22
US10792285B2 (en) 2020-10-06
JP2022107687A (ja) 2022-07-22
JP2019502751A (ja) 2019-01-31
US20200261458A1 (en) 2020-08-20
KR101693675B1 (ko) 2017-01-06
EP3391908A4 (en) 2019-08-07

Similar Documents

Publication Publication Date Title
KR101260636B1 (ko) 안정화된 페메트렉시드 제제
KR101485243B1 (ko) 안정화된 페메트렉시드 제제
JP2022107687A (ja) ペメトレキセドまたはその薬剤学的に許容可能な塩を含有する安定化された薬学組成物
US20030212083A1 (en) Pharmaceutical composition
EP1265612B1 (en) Pharmaceutical composition comprising pemetrexed together with monothioglycerol, l-cystein or thioglycolic acid
KR102004341B1 (ko) 약제학적 페메트렉시드 액제
CN101500571A (zh) 稳定的冻干制剂
KR20130122065A (ko) 페메트렉시드를 함유하는 안정화된 주사용 액상 제제
CN105979949A (zh) 不含抗氧化剂的药物组合物及其制备方法
JP2019502751A5 (https=)
CA3137265A1 (en) A stable, ready to use aqueous pharmaceutical composition of pemetrexed
GB2358799A (en) A pharmaceutical composition comprising pemetrexed and an antioxidant
EP3222271A1 (en) Stable pharmaceutical composition comprising pemetrexed or pharmaceutically acceptable salt thereof
GB2365768A (en) Stable liquid composition containing pemetrexed

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1255313

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20180828

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1255313

Country of ref document: HK